Pharma Focus Asia

Samsung BioLogics Announces US$148 Million Manufacturing Contract for its Plant 3 Facility


Samsung BioLogics announced that it has entered into US$148 Million manufacturing contract for its Plant 3 facility.


The Plant 3 facility has a total capacity of 180,000 liters and is expected to be cGMP operational by the fourth quarter of 2018.

The products from the plant 1 (6 x 5,000 L) and Plant 2 (10 x 15,000 L) facilities mature, Plant 3 will be utilised to supply satisfy the demand of clients.

The third plant, which was completed in November, is the world’s biggest single-site biologics drug manufacturing facility.

It will go online in 2020 and is expected to have the world’s largest capacity for a biologics contract manufacturing organisation, with total production capacity hitting 362,000 liters.

Adding of 18, 000L of stainless steel bioreactor capacity effectively doubles the total capacity across Samsung BioLogics other two plants.

The plant expansion plans focus on progress made in the development of Alzheimer’s disease therapies.


NameSamsung BioLogics
LocationSouth Korea
TypeManufacturing Contract
Parties InvolvedSamsung BioLogics
BudgetUS$148 Million
Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?